William J.  Ferenczy net worth and biography

William Ferenczy Biography and Net Worth

SVP of QuidelOrtho
William Ferenczy became Senior Vice President, Cardiometabolic Business Unit in April 2020. He joined Quidel in 2011 as Senior Director, US Marketing and subsequently held positions as Senior Director and General Manager, Savanna and Vice President, Strategy and Global Product Management. Mr. Ferenczy has over 30 years of experience leading product launches and market development across a wide range of diagnostic companies including Abbott Diagnostics, Biosite Diagnostics, Nanosphere and Inovise Medical. Early in his career, he held several manufacturing management positions of increasing responsibility at Abbott Hospital Products and General Medical Manufacturing. Mr. Ferenczy hold a B.S. in Pre-professional Studies from the University of Notre Dame.

What is William J. Ferenczy's net worth?

The estimated net worth of William J. Ferenczy is at least $234,419.02 as of May 3rd, 2021. Mr. Ferenczy owns 6,127 shares of QuidelOrtho stock worth more than $234,419 as of April 18th. This net worth estimate does not reflect any other assets that Mr. Ferenczy may own. Learn More about William J. Ferenczy's net worth.

How old is William J. Ferenczy?

Mr. Ferenczy is currently 68 years old. There are 6 older executives and no younger executives at QuidelOrtho. Learn More on William J. Ferenczy's age.

How do I contact William J. Ferenczy?

The corporate mailing address for Mr. Ferenczy and other QuidelOrtho executives is 9975 SUMMERS RIDGE ROAD, SAN DIEGO CA, 92121. QuidelOrtho can also be reached via phone at (800) 874-1517 and via email at [email protected]. Learn More on William J. Ferenczy's contact information.

Has William J. Ferenczy been buying or selling shares of QuidelOrtho?

William J. Ferenczy has not been actively trading shares of QuidelOrtho during the past quarter. Most recently, William J. Ferenczy sold 803 shares of the business's stock in a transaction on Monday, May 3rd. The shares were sold at an average price of $105.74, for a transaction totalling $84,909.22. Following the completion of the sale, the senior vice president now directly owns 6,127 shares of the company's stock, valued at $647,868.98. Learn More on William J. Ferenczy's trading history.

Who are QuidelOrtho's active insiders?

QuidelOrtho's insider roster includes Michael Abney, Jr. (SVP), Douglas Bryant (CEO), William Ferenczy (SVP), Werner Kroll (SVP), Edward Michael (Director), Mary Polan (Director), Charles Slacik (Director), Randall Steward (CFO), and Matthew Strobeck (Director). Learn More on QuidelOrtho's active insiders.

Are insiders buying or selling shares of QuidelOrtho?

During the last year, QuidelOrtho insiders bought shares 1 times. They purchased a total of 2,150 shares worth more than $99,652.50. The most recent insider tranaction occured on February, 23rd when CFO Joseph M Busky bought 2,150 shares worth more than $99,652.50. Insiders at QuidelOrtho own 1.0% of the company. Learn More about insider trades at QuidelOrtho.

Information on this page was last updated on 2/23/2024.

William J. Ferenczy Insider Trading History at QuidelOrtho

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/3/2021Sell803$105.74$84,909.226,127View SEC Filing Icon  
3/17/2021Sell7,400$136.06$1,006,844.00View SEC Filing Icon  
See Full Table

William J. Ferenczy Buying and Selling Activity at QuidelOrtho

This chart shows William J Ferenczy's buying and selling at QuidelOrtho by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

QuidelOrtho Company Overview

QuidelOrtho logo
QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point-of-Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, which measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing products to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point-of-Care business unit provides instruments and tests to provide rapid results across a continuum of point-of-care settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, and internationally. The company was incorporated in 1979 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $38.26
Low: $38.10
High: $39.09

50 Day Range

MA: $47.05
Low: $38.71
High: $69.54

2 Week Range

Now: $38.26
Low: $38.10
High: $95.02

Volume

1,039,114 shs

Average Volume

1,008,521 shs

Market Capitalization

$2.56 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.11